PLIANT THERAPEUTICS, INC.

Listed Company

PLRXCIK 0001746473NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-149.34M

Total Assets

$225.23M

Equity

$181.21M

Shares Out

61.91M

Op. Cash Flow

$-128.34M

Business

PLIANT THERAPEUTICS, INC. develops novel therapeutics targeting fibrotic diseases. It focuses on discovery and development of small‑molecule drug candidates, with lead product candidate bexotegrast, and conducts preclinical studies, clinical trials and related regulatory activities toward potential approval. Its key business activities comprise research and development, clinical development, intellectual property management and collaborative partnerships with contract research organizations and contract manufacturers. The company pursues clinical and commercial opportunities internationally and relies on third‑party suppliers, clinical trial networks and commercial partners, including single‑source suppliers in foreign jurisdictions such as China.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0	0	2	10	8
Research and development	−109	−169	−128	−97	−78
General and administrative	−47	−59	−58	−40	−28
Total operating expenses	−156	−228	−186	−137	−105
Loss from operations	−156	−228	−184	−127	−98
Interest and other income (expense), net	11	21	24	5	272,000
Interest expense	−3	−3	−1	−791,000	—
Loss on extinguishment of debt (Note 7)	−2	0	—	—	—
Net loss	−149	−210	−161	−123	−97
Net loss per share - basic (USD per share)	−2.43	−3.47	−2.75	−2.94	−2.71
Net loss per share - diluted (USD per share)	−2.43	−3.47	−2.75	−2.94	−2.71
Weighted average shares used in computing net loss per share - basic (in shares)	61	61	59	42	36
Weighted average shares used in computing net loss per share - diluted (in shares)	61	61	59	42	36
Net unrealized loss on short-term investments	−336,000	−24,000	2	−2	−169,000
Total other comprehensive loss	−336,000	−24,000	2	−2	−169,000
Comprehensive loss	−150	−210	−159	−125	−97

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	45	71	63	34	52
Short-term investments	145	285	431	298	149
Prepaid expenses and other current assets (Note 5)	4	7	11	7	7
Property and equipment held for sale (Note 4)	1	0	—	—	—
Total current assets	196	362	506	340	209
Property and equipment, net (Note 4)	3	6	4	4	5
Operating lease right-of-use assets	24	27	1	5	6
Restricted cash	1	1	1	0	—
Other non-current assets	392,000	435,000	392,000	394,000	838,000
Total assets	225	397	512	351	221
Accounts payable	480,000	6	5	2	3
Accrued research and development	5	14	12	11	6
Accrued liabilities (Note 6)	10	12	10	9	12
Lease liabilities, current	1	542,000	1	2	2
Total current liabilities	16	33	29	24	17
Lease liabilities, non-current	28	29	0	3	5
Long-term debt (Note 7)	0	30	10	10	0
Total liabilities	44	93	39	37	22
Commitments and Contingencies (Note 14)	—	—	—	—	—
Preferred stock, $0.0001 par value 10,000,000 shares authorized at December 31, 2025 and 2024, none issued or outstanding at December 31, 2025 and 2024	0	0	0	0	—
Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2025 and 2024; and 61,449,290 and 60,860,838 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively;	6,000	6,000	6,000	5,000	3,000
Additional paid-in capital	1,041	1,014	973	654	414
Accumulated deficit	−859	−710	−500	−338	−215
Accumulated other comprehensive (loss) gain	−15,000	321,000	345,000	−2	−201,000
Total stockholders equity	181	304	474	313	199
Total liabilities and stockholders equity	225	397	512	351	221

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	2	2	2	2	2
Stock-based compensation expense	26	38	44	23	10
Gain on sale of property plant and equipment	−44,000	0	—	—	—
Non-cash operating lease expense	3	3	2	2	2
Amortization (accretion) on short-term investments	4	3	−5	−2	1
Prepaid expenses and other current assets	3	5	−4	−294,000	−2
Other non-current assets	43,000	−43,000	0	201,000	70,000
Accounts payable	−5	1	3	−1	891,000
Accrued liabilities	−12	4	3	8	3
Operating lease liabilities	−876,000	−820,000	−3	−2	−2
Net cash used in operating activities	−128	−156	−116	−95	−75
Purchase of short-term investments	−203	−211	−583	−326	−220
Maturity of short-term investments	338	355	457	177	296
Purchase of property and equipment	−374,000	−4	−921,000	−2	−2
Proceeds from sale of property, plant and equipment	155,000	0	—	—	—
Net cash provided by investing activities	134	140	−127	−150	74
Proceeds from issuances of common stock under benefit plans	570,000	3	5	1	3
Payment of debt	−32	0	—	—	—
Proceeds from term loan, net of issuance costs	0	20	0	10	0
Net cash (used in) provided by financing activities	−32	23	274	227	3
Net (decrease) increase in cash and cash equivalents	−26	8	31	−18	783,000
Cash paid for interest	3	3	1	615,000	0
Purchase of property and equipment in accounts payable	112,000	236,000	0	0	57,000
Cash paid for operating lease liabilities in operating cash flows	6	5	4	3	2
Right-of-use assets obtained in exchange for new operating lease liabilities	0	30	0	950,000	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro